2025 China Pharmaceutical CDMO Industry Insight Blue Book
On April 30, 2024, Sapalizumab's new commercial production facility has officially obtained approval from the National Medical Products Administration (NMPA) of China. This marks the initiation of the commercialization process supported by Chime Biologics to assist clients in obtaining approval for their drugs to enter the market. Currently, Chime Biologics has 12 late-stage projects in progress.
Contact Info
Fill in the information in the form, and we will provide you with more accurate recommendation information.
I understand and agree to use and transfer my personal information in accordance with the privacy statement